Who is a candidate for high-dose interleukin-2 therapy for kidney cancer?

High-dose interleukin-2 (IL-2) therapy is Food and Drug Administration (FDA)-approved and is considered standard treatment for patients with metastatic renal cell carcinoma.
Kidney cancer patients suitable for high-dose IL-2 treatment:
  • Must be diagnosed with metastatic kidney cancer (cancer that has spread to other parts of the body)
  • Must be out of bed more than 50 percent of the day
  • Have relatively normal function of heart, lungs, kidneys, and liver
  • Have brain metastases treated and stable
  • Should not take/use steroids or steroid-containing compounds